Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
2004-9-17
pubmed:abstractText
FDA reviewers need a means to rapidly predict organ-specific carcinogenicity to aid in evaluating new chemicals submitted for approval. This research addressed the building of a database to use in developing a predictive model for such an application based on structure-activity relationships (SAR). The Internet availability of the Carcinogenic Potency Database (CPDB) provided a solid foundation on which to base such a model. The addition of molecular structures to the CPDB provided the extra ingredient necessary for SAR analyses. However, the CPDB had to be compressed from a multirecord to a single record per chemical database; multiple records representing each gender, species, route of administration, and organ-specific toxicity had to be summarized into a single record for each study. Multiple studies on a single chemical had to be further reduced based on a hierarchical scheme. Structural cleanup involved removal of all chemicals that would impede the accurate generation of SAR type descriptors from commercial software programs; that is, inorganic chemicals, mixtures, and organometallics were removed. Counterions such as Na, K, sulfates, hydrates, and salts were also removed for structural consistency. Structural modification sometimes resulted in duplicate records that also had to be reduced to a single record based on the hierarchical scheme. The modified database containing 999 chemicals was evaluated for liver-specific carcinogenicity using a variety of analysis techniques. These preliminary analyses all yielded approximately the same results with an overall predictability of about 63%, which was comprised of a sensitivity of about 30% and a specificity of about 77%.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1528-7394
pubmed:author
pubmed:copyrightInfo
Copyright Taylor & Francis Inc.
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
67
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1363-89
pubmed:dateRevised
2006-2-16
pubmed:meshHeading
pubmed-meshheading:15371237-Animals, pubmed-meshheading:15371237-Carcinogens, pubmed-meshheading:15371237-Data Compression, pubmed-meshheading:15371237-Data Interpretation, Statistical, pubmed-meshheading:15371237-Databases, Factual, pubmed-meshheading:15371237-Discriminant Analysis, pubmed-meshheading:15371237-Drug Approval, pubmed-meshheading:15371237-Drug Evaluation, Preclinical, pubmed-meshheading:15371237-Humans, pubmed-meshheading:15371237-Internet, pubmed-meshheading:15371237-Liver, pubmed-meshheading:15371237-Models, Chemical, pubmed-meshheading:15371237-Molecular Structure, pubmed-meshheading:15371237-Molecular Weight, pubmed-meshheading:15371237-Organ Specificity, pubmed-meshheading:15371237-Predictive Value of Tests, pubmed-meshheading:15371237-Sensitivity and Specificity, pubmed-meshheading:15371237-Structure-Activity Relationship, pubmed-meshheading:15371237-Toxicity Tests, pubmed-meshheading:15371237-Toxicology, pubmed-meshheading:15371237-United States, pubmed-meshheading:15371237-United States Food and Drug Administration
pubmed:year
2004
pubmed:articleTitle
Building an organ-specific carcinogenic database for SAR analyses.
pubmed:affiliation
Division of Biometry and Risk Assessment, Food and Drug Administration, National Center for Toxicological Research, Jefferson, Arkansas, USA. jyoung@nctr.fda.gov
pubmed:publicationType
Journal Article, Validation Studies